Skip to main content
. 2021 May 5;125(1):94–100. doi: 10.1038/s41416-021-01399-6

Table 3.

Comparison of KRAS mutational status in FFPE tumoral tissues and cfDNA.

Tumour tissue Plasma
pt id FFPE TISSUE
KRAS mutations
cfDNA
KRAS mutations
cfDNA
KRAS allele frequency
COL 01 KRAS p.G12D KRAS p.G12D 0.83
COL 02 KRAS p.G12C KRAS p.G12C 65.26
COL 03 KRAS p.G12A KRAS p.G12A 7.25
COL 04 KRAS p.G12D KRAS p.G12D 30.33
COL 05 KRAS p.G13D KRAS p.G13D 13.68
COL 06 KRAS p.G12C KRAS p.G12C 1.92
COL 07 KRAS p.G12S KRAS p.G12S 38.19
COL 08 KRAS p.G12D KRAS p.G12D 1.36
COL 09 KRAS p.G13D KRAS p.G13D 28.78
COL 10 KRAS p.G13D KRAS p.G13D 2.40
COL 11 KRAS p.G12D KRAS p.G12D 2.78
COL 12 KRAS p.G12A KRAS p.G12A 38.00
COL 13 KRAS p.G13D KRAS p.G13D 0.38
KRAS p.G12D 1.88
COL 14 KRAS p.G12A KRAS p.G12D 1.83
COL 15 KRAS p.G13V WT
COL 16 KRAS p.G12D KRAS p.G12D 0.56
COL 17 KRAS p.A146K WT
COL 18 KRAS p.G12D KRAS p.G12D 21.81
COL 19 KRAS p.G12C KRAS p.G12C 10.75
COL 20 KRAS p.G12D nd nd

FFPE  formalin fixed paraffin emebedded, nd  not determined.